An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
← catalyst calendarNCT03989947 · readout ≤ 4,303 d
Sponsored by BioMarin Pharmaceutical (industry) · BMRN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
73actual
Sites
16
Countries
Australia, Japan, United Kingdom +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-06-12 | actual | When the study began enrolling |
| Primary completion | May 2038 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2038 | estimated | The whole study's end, after follow-up |
| First posted | 2019-06-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Achondroplasia
Intervention
- Drug: Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily. — also filed as Vosoritide
Primary outcomes
what the primary-completion date above is the date OFEvaluate the incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
measured "Through study completion, an average of 5 years"
Evaluate change in height/length z-score in children with ACH treated with BMN 111
measured "Through study completion, an average of 5 years"
Permalink · BMRN's whole pipeline · Catalyst calendar · Every registered study · What changed